# Cholangiocarcinoma

Manage cholangiocarcinoma by defining intrahepatic, perihilar, or distal anatomy; obtaining high-quality staging before biliary intervention when feasible; securing diagnosis without compromising curative options; determining resectability in a multidisciplinary setting; relieving clinically consequential obstruction; and profiling unresectable or metastatic disease for biomarker-directed therapy.

**Clinical question:** How should physicians diagnose, stage, drain, and select definitive or systemic treatment for cholangiocarcinoma?

Updated: 2026-09-16T00:47:58.013646+00:00

## What matters in practice
- Classify disease as intrahepatic, perihilar, or distal cholangiocarcinoma because anatomic location determines staging, drainage route, operative strategy, and molecular treatment opportunities. [11][16]
- Obtain high-resolution cross-sectional imaging for staging and resectability assessment before biliary drainage whenever clinical urgency permits. [5][18]
- Do not treat a negative ERCP brushing or biopsy as exclusion of extrahepatic cholangiocarcinoma; standard brush cytology and biopsy have limited sensitivity in desmoplastic strictures. [16]
- Drain acute cholangitis, severe pruritus, marked hyperbilirubinemia, or obstruction that delays planned distal cholangiocarcinoma surgery; use ERCP first when feasible and reserve percutaneous drainage for failed, inadequate, or infeasible endoscopic drainage. [7][8]
- Send comprehensive molecular testing for unresectable or metastatic biliary tract cancer, including MMR status, HER2 testing, and next-generation sequencing for FGFR2 fusions, IDH1 mutations, and NTRK alterations. [23]

## Separate urgent biliary sepsis from staging and curative-intent planning

The first decision is whether obstruction requires immediate decompression or can await definitive imaging and multidisciplinary review.

In a patient with obstructive jaundice and suspected cholangiocarcinoma, prioritize biliary decompression for acute cholangitis, hepatic decompensation that prevents oncologic therapy, or clinically consequential biliary obstruction. Endoscopic biliary drainage is the usual initial approach in Western practice; use percutaneous transhepatic biliary drainage when endoscopic drainage fails, is inadequate, or is not feasible. [8]

If the patient is clinically stable, obtain high-quality contrast-enhanced cross-sectional imaging before manipulating the biliary tree. Imaging defines tumor location, vascular involvement, liver remnant requirements, metastatic disease, and operative feasibility; it is specifically required for accurate staging and resectability assessment in perihilar and intrahepatic disease. [5][18]

Route the case early to a hepatobiliary multidisciplinary team when imaging suggests potentially resectable disease. Complete resection remains the curative treatment option, whereas unresectable disease is managed with palliation, systemic therapy, and selected local or investigational approaches. [9][16]
- Do not place a primary metal stent in an unverified malignant stricture when future ERCP or percutaneous biopsy, brachytherapy, or endobiliary ablation at that site may be needed. [8]
- After any biliary intervention, monitor for pancreatitis, cholangitis, cholecystitis, bleeding, perforation, aspiration-related events, and stent dysfunction. [5]

*Initial branching decisions in suspected cholangiocarcinoma. [5][7][8][18]*

| Clinical situation | Immediate action | What changes next |
| --- | --- | --- |
| Acute cholangitis or obstruction causing hepatic decompensation | Urgently decompress the biliary system; ERCP is generally the initial route, with percutaneous drainage after failed, inadequate, or infeasible endoscopic drainage. [8] | Reassess bilirubin, clinical recovery, and ability to proceed with surgery or oncologic treatment. [8] |
| Stable suspected perihilar or intrahepatic disease | Perform high-resolution cross-sectional imaging before drainage when possible. [5][18] | Use anatomic extent and vascular/liver-remnant assessment for resectability planning. [5] |
| Indeterminate stricture without histologic confirmation | Obtain tissue strategically during ERCP or cholangioscopy-directed sampling rather than assuming a negative standard sample excludes cancer. [5][16] | Avoid irreversible stent choices that could obstruct subsequent sampling or local procedures. [8] |

## Use tumor location to select the diagnostic and surgical pathway

Intrahepatic, perihilar, and distal tumors are clinically distinct branches rather than interchangeable biliary tract cancers.

Intrahepatic cholangiocarcinoma arises within the liver and is commonly evaluated as a hepatic mass requiring assessment of intrahepatic distribution, vascular anatomy, extrahepatic spread, and adequacy of future liver remnant before a resection decision. Multifocal intrahepatic disease creates a different problem from a solitary resectable lesion; comparative observational data have evaluated hepatic arterial infusion pump chemotherapy against resection in multifocal disease, underscoring that surgical selection cannot be based on histology alone. [4][22]

Perihilar cholangiocarcinoma requires especially detailed mapping of longitudinal biliary extension, portal and arterial relationships, and the future liver remnant. If resection is planned, major hepatectomy with bile duct resection and regional lymphadenectomy has been associated with a reported 26% actual 5-year survival in a surgical series. [2][5]

Distal cholangiocarcinoma is approached through the distal bile duct pathway, with attention to feasibility of transpapillary drainage and the operative implications of local extension. For resectable distal disease, routine preoperative biliary drainage is not mandatory; reserve it for acute cholangitis, intractable pruritus, bilirubin greater than 14.6 mg/dL, or an anticipated surgical delay beyond 4 weeks. [7]
- For perihilar and intrahepatic disease, assess whether biliary drainage and future liver remnant augmentation are needed before major resection. [5]
- For distal disease requiring preoperative drainage, ERCP placement of a fully covered self-expandable metal stent is described; perihilar drainage uses one or more plastic stents when endoscopic drainage is selected. [7]
- When transpapillary drainage cannot be achieved, consider EUS-guided biliary drainage; reserve percutaneous transhepatic drainage when EUS-guided drainage is unavailable or technically infeasible. [7]

*Anatomic branch points that alter drainage and curative-intent planning. [2][5][7][16]*

| Location | Preoperative priority | Drainage implication |
| --- | --- | --- |
| Intrahepatic cholangiocarcinoma | Define intrahepatic tumor distribution, vascular anatomy, extrahepatic disease, and future liver remnant before resection selection. [5][22] | Drain only when clinically needed for obstruction or treatment readiness; determine approach from biliary anatomy and access. [8] |
| Perihilar cholangiocarcinoma | Map ductal and vascular extent and determine whether future liver remnant augmentation is needed. [5] | If drainage is needed, ERCP with plastic stenting is an option; percutaneous drainage is used when endoscopic or EUS-guided access is unsuccessful or infeasible. [7][8] |
| Distal cholangiocarcinoma | Do not routinely drain before resection unless cholangitis, refractory pruritus, bilirubin >14.6 mg/dL, or surgical delay >4 weeks is present. [7] | Use ERCP with a fully covered self-expandable metal stent when preoperative drainage is indicated. [7] |

## Confirm malignancy without allowing a low-sensitivity sample to terminate the workup

Diagnostic failure is common in infiltrative extrahepatic tumors and must be managed as a sampling problem.

For suspected hilar cholangiocarcinoma, minimum diagnostic and staging evaluation includes CA 19-9 measurement and high-quality cross-sectional imaging, preferably before biliary intervention. Interpret CA 19-9 cautiously in obstructed patients because cholestasis can cause false-positive elevation; it should not independently establish malignancy. [18][16]

Use ERCP-based brush cytology and tissue sampling when pathology will alter treatment selection or when a benign stricture remains plausible. Standard brush cytology and biopsy are limited by tumor desmoplasia, surrounding inflammation, sampling quality, and low sensitivity; reported sensitivities are approximately 45% for brush cytology and 48% for biopsy in extrahepatic cholangiocarcinoma. [16]

Escalate an unresolved, high-suspicion stricture to targeted sampling strategies rather than reassuring on negative brushing alone. Concurrent cholangioscopy can provide histologic sampling, and, in primary sclerosing cholangitis, the diagnostic approach integrates ERCP with brush cytology and fluorescence in situ hybridization, plus radiographic findings and CA 19-9 or CEA. [5][15]

In PSC-associated suspected cholangiocarcinoma, distinguish a dominant inflammatory or fibrotic stricture from malignancy through integrated imaging, ERCP-based sampling, cytology, and FISH rather than a single test result. Emerging DNA methylation assays have shown diagnostic signal in research cohorts but require broader prospective validation before replacing established pathways. [15][19]
- Plan tissue acquisition before placing a metal stent if future biopsy, local endobiliary therapy, or brachytherapy may be required at the stricture. [8]
- Treat a malignant cytology or histology result as confirmatory; treat negative or nondiagnostic sampling as nonexclusion when imaging and clinical findings remain suspicious. [16]
- In a PSC patient with suspected cancer, include FISH with brush cytology during ERCP-based evaluation. [15]

*Interpretation of commonly used diagnostic tools for suspected cholangiocarcinoma. [5][14][15][16][18]*

| Test or procedure | Useful result | Important limitation or next step |
| --- | --- | --- |
| Contrast-enhanced cross-sectional imaging | Defines location, extent, staging, and resectability features. [5][18] | Obtain before drainage if the patient does not require urgent decompression. [18] |
| CA 19-9 | Part of the minimum workup for suspected hilar disease. [18] | Cholestasis can cause false-positive elevation; do not use alone to establish malignancy. [16] |
| ERCP brush cytology and biopsy | A positive malignant result supports diagnosis. [16] | Sensitivity is limited; reported sensitivity is approximately 45% for brushing and 48% for biopsy, so negative sampling requires further evaluation if suspicion persists. [16] |
| Cholangioscopy-directed sampling | Can provide histologic sampling during endoscopic evaluation. [5] | Use when conventional ERCP sampling remains nondiagnostic and tissue confirmation changes management. [5] |
| Brush cytology plus FISH in PSC | Part of an integrated PSC-associated cholangiocarcinoma evaluation. [15] | Interpret with imaging and tumor markers; no isolated test resolves all indeterminate PSC strictures. [15] |

## Select resection candidates and use biliary drainage to enable—not delay—definitive treatment

Curative-intent care depends on resectability, liver reserve, and safe control of obstructive complications.

Offer surgical evaluation to patients without unresectable local anatomy or distant disease on high-quality staging. For perihilar tumors, the curative-intent operation may require major partial hepatectomy, bile duct resection, and regional lymphadenectomy; operative planning should incorporate the functional future liver remnant and the need for preoperative drainage or augmentation. [2][5]

Use preoperative biliary drainage selectively rather than reflexively. In distal cholangiocarcinoma, drainage is recommended for acute cholangitis, intractable pruritus, bilirubin greater than 14.6 mg/dL, or surgery delayed more than 4 weeks; routine drainage in otherwise resectable distal disease is not mandatory. [7]

For unresectable perihilar cholangiocarcinoma with biliary obstruction, pursue palliative stenting by ERCP or percutaneous transhepatic cholangiography and drainage. Endobiliary radiofrequency ablation and photodynamic therapy have been used individually to improve local tumor control and biliary strictures, but they should not substitute for systemic treatment selection or durable drainage planning. [7][6]
- Choose drainage access based on anatomy, endoscopic feasibility, and availability of EUS-guided drainage; do not assume that one route is appropriate for every hilar obstruction. [7][8]
- Anticipate stent blockage and nonocclusion complications, including cholangitis, cholecystitis, bleeding, ulceration, penetration, and perforation. [5]
- When repeated endobiliary radiofrequency ablation is used, published practice has repeated treatment every 3 to 4 months when feasible, with concomitant stenting for drainage. [6]

*Drainage selection in cholangiocarcinoma-associated obstruction. [5][7][8]*

| Scenario | Preferred approach | Escalation or caution |
| --- | --- | --- |
| Resectable distal cholangiocarcinoma without cholangitis, severe pruritus, bilirubin >14.6 mg/dL, or delay >4 weeks | Proceed toward surgery without routine preoperative drainage. [7] | Drain if one of the stated clinical triggers develops. [7] |
| Distal cholangiocarcinoma requiring drainage | ERCP with a fully covered self-expandable metal stent. [7] | Monitor for ERCP and stent-related complications. [5] |
| Perihilar obstruction requiring endoscopic drainage | ERCP with one or more plastic stents. [7] | Use EUS-guided drainage if transpapillary access fails; use percutaneous drainage if EUS-guided drainage is unavailable or infeasible. [7] |
| Endoscopic drainage failure or inadequate drainage | Use percutaneous transhepatic biliary drainage. [8] | Recognize risks including portal vein injury, catheter-tract recurrence, and peritoneal dissemination reported with percutaneous approaches. [5] |

## Obtain comprehensive molecular profiling before selecting subsequent systemic therapy

Advanced-disease treatment requires parallel management of biliary patency, performance status, and actionable tumor biology.

For unresectable or metastatic biliary tract cancer, obtain comprehensive molecular profiling early enough to guide therapy at progression or when systemic options are being selected. Recommended testing includes MMR assessment by immunohistochemistry or PCR, HER2 assessment by immunohistochemistry with in situ hybridization for equivocal cases, and next-generation sequencing for FGFR2 fusions, IDH1 mutations, and NTRK alterations. [23]

If tissue is insufficient or prior operative or biopsy material is unavailable, circulating tumor DNA profiling is an alternative for identifying actionable alterations. A negative plasma result should be interpreted in clinical context because tumor-derived DNA detection can be limited; pursue tissue-based profiling when feasible and when a result would change treatment. [23]

Match subsequent therapy to the alteration and prior treatment course rather than treating cholangiocarcinoma as molecularly uniform. Molecularly selected options discussed for biliary tract cancer include pembrolizumab for dMMR tumors; HER2-directed approaches including trastuzumab plus pertuzumab, zanidatamab, trastuzumab deruxtecan, and tucatinib plus trastuzumab; and targeted therapy pathways for FGFR2 fusions, IDH1 mutations, and NTRK alterations. [23]

Continue to reassess biliary drainage during systemic treatment because obstruction can produce recurrent cholangitis, worsen cholestasis, and preclude oncologic therapy. In advanced extrahepatic disease, metal or plastic stents are used to maintain decompression and reduce obstructive cholangitis risk. [6][8]
- Document MMR status with IHC or PCR before considering checkpoint inhibitor treatment for a dMMR tumor. [23]
- For equivocal HER2 immunohistochemistry, perform in situ hybridization before assigning HER2-directed treatment. [23]
- Consider clinical trials when molecular testing does not yield an actionable alteration or after resistance to targeted therapy; acquired secondary FGFR2 mutations can reduce FGFR inhibitor effectiveness. [23]

*Molecular workup that can alter therapy in unresectable or metastatic biliary tract cancer. [23]*

| Biomarker assessment | Testing method | Therapeutic implication |
| --- | --- | --- |
| dMMR | MMR immunohistochemistry or PCR. [23] | Identifies tumors that may respond to pembrolizumab. [23] |
| HER2 | Immunohistochemistry; in situ hybridization for equivocal results. [23] | Supports consideration of HER2-directed regimens, including trastuzumab-based approaches, zanidatamab, trastuzumab deruxtecan, or tucatinib plus trastuzumab. [23] |
| FGFR2 fusion | Next-generation sequencing. [23] | Identifies a targeted-therapy pathway; secondary FGFR2 mutations may mediate resistance. [23] |
| IDH1 mutation or NTRK alteration | Next-generation sequencing. [23] | Identifies molecularly selected targeted-treatment pathways. [23] |
| Insufficient tissue | Circulating tumor DNA profiling. [23] | Alternative means of detecting actionable alterations when tissue is unavailable. [23] |

## Common questions

### Should a negative ERCP brushing stop the cholangiocarcinoma evaluation?

No. Extrahepatic cholangiocarcinoma frequently yields false-negative standard samples because of desmoplasia, local inflammation, and sampling limitations; reported sensitivities are approximately 45% for brush cytology and 48% for biopsy. If imaging and clinical suspicion persist, escalate to repeat or targeted sampling such as cholangioscopy-directed biopsy. [5][16]

### When should a resectable distal cholangiocarcinoma be drained before surgery?

Do not drain routinely. Preoperative drainage is recommended for acute cholangitis, intractable pruritus, serum bilirubin greater than 14.6 mg/dL, or an expected surgery delay beyond 4 weeks. [7]

## References
1. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced ... — jamanetwork.com — https://jamanetwork.com/journals/jamaoncology/fullarticle/2698042
2. Major Hepatic Resection for Hilar Cholangiocarcinoma — jamanetwork.com — https://jamanetwork.com/journals/jamasurgery/fullarticle/396768
3. Adjuvant Chemoradiation and Immunotherapy for Extrahepatic ... — jamanetwork.com — https://jamanetwork.com/journals/jamaoncol/articlepdf/10.1001/jamaoncol.2025.1926
4. Hepatic Arterial Infusion Pump Chemotherapy vs Resection for ... — jamanetwork.com — https://jamanetwork.com/journals/jamasurgery/fullarticle/2792166
5. British Society of Gastroenterology guidelines for the diagnosis ... - Gut — gut.bmj.com — https://gut.bmj.com/content/gutjnl/73/1/16.full.pdf
6. Impact of regular additional endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-021-04297-2
7. Cholangiocarcinoma 2026: status quo, unmet needs and priorities | Nature Reviews Gastroenterology & Hepatology — www.nature.com — https://www.nature.com/articles/s41575-025-01153-w
8. Prognostic factors for survival in patients with advanced cholangiocarcinoma treated with percutaneous transhepatic drainage | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-025-86443-8
9. Cholangiocarcinoma 2020: the next horizon in mechanisms and management | Nature Reviews Gastroenterology & Hepatology — www.nature.com — https://www.nature.com/articles/s41575-020-0310-z
10. Evaluation and Management of Intrahepatic and Extrahepatic ... — acsjournals.onlinelibrary.wiley.com — https://acsjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.29692
11. The multidisciplinary management of cholangiocarcinoma — acsjournals.onlinelibrary.wiley.com — https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.34541
12. Anatomical, histomorphological and molecular classification of ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111%2Fliv.14093
13. Intrahepatic Cholangiocarcinoma: Epidemiological Trends, Risk ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/jgh.70357
14. Diagnostic power of DNA methylation markers suggestive of cholangiocarcinoma in ERCP-based brush cytology - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0016510721014851
15. Pathogenesis, diagnosis and treatment of premalignant and malignant stages of cholangiocarcinoma in primary sclerosing cholangitis — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111%2Fliv.14180
16. Extra-hepatic cholangiocarcinoma diagnosis: from classical pathological analysis to the emerging omics tests - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0748798326003896
17. Fluorescence in situ hybridization in diagnostic cytology - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S004681770700216X
18. Hilar Cholangiocarcinoma: expert consensus statement — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1365182X15312478
19. Early and accurate detection of cholangiocarcinoma in... : Hepatology — journals.lww.com — https://journals.lww.com/hep/fulltext/2022/01000/early_and_accurate_detection_of_cholangiocarcinoma.7.aspx
20. Brush Cytology During ERCP for the Diagnosis of... : American Journal of Gastroenterology — journals.lww.com — https://journals.lww.com/ajg/fulltext/10.1038/ajg.2018.320~brush-cytology-during-ercp-for-the-diagnosis-of-biliary-and
21. Endoscopic considerations for the management of ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/lci2.40
22. Advances in the treatment of intrahepatic cholangiocarcinoma: An ... — acsjournals.onlinelibrary.wiley.com — https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21759
23. Intrahepatic cholangiocarcinoma: Insights on... : Hepatology Communications — journals.lww.com — https://journals.lww.com/hepcomm/fulltext/2025/07010/intrahepatic_cholangiocarcinoma__insights_on.5.aspx
24. How I Do It: Systemic Therapies for Primary Liver Cancers | Radiology — pubs.rsna.org — https://pubs.rsna.org/doi/10.1148/radiol.251371

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.